Hammernews bei LAMP - 500 Beiträge pro Seite

[carlomania]

LEWISTON, N.Y., April 21 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it has received notification from the United States Patent and Trademark Office that LAM has been granted a patent for Topical Drug Preparations, patent number 6,723,345. The patent covers L.A.M. Ionic Polymer Matrix(TM) in its stable, sterile gelled composition as a transdermal delivery system designed to deliver therapeutic levels of a drug to specific sites below the dermal level of the skin.

"This is the fifteenth patent LAM has been issued in the United States, underscoring the Company``s commitment to its intellectual property assets," stated Joseph Slechta, President and Chief Executive Officer of LAM. "This robust intellectual property library will enable LAM to continue to develop additional products to expand the Company``s product offering."

Mr. Slechta concluded, "LAM IPM Wound Gel has proven to have a high level of efficacy in treating a variety of hard to heal wounds including diabetic ulcers and skin tears. We are making steady progress in securing partners to distribute LAM``s products and are very optimistic about our prospects."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., http://www.lampharm.com/, is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 15 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company``s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

Contact: Stephanie Carrington (Investors/Media) 646-536-7017 The Ruth Group

LAM Pharmaceutical, Corp.

© PR Newswire


Klicken Sie hier, um weitere aktuelle Nachrichten zum Unternehmen zu finden:

LAM PHARMACEUTICAL

[carlomania]

Riecht nach ausbruch




Ask bei 0,29Euro

[carlomania]

Da könnte sich ein schönes W abzeichnen.

Die tage sollen neue news kommen, dann müsste der Dollar zu packen sein

[alexian]

carlo, ich find es zum kotzen...sei doch mal realistischer, du denkst doch nicht im ernst, dass in paar tagen der dollar zu knacken sein wird...

bei gegebenfalls tatsächlich vorhandener euphorie sollte niemend mit solcher aussage geblendet werden...

nur meine meinung

a.

[carlomania]

Think Positiv, Slechts wirds schon richten


Ohen news sind wir im Januar über 0,60$ gestiegen.

warte mal ab

[carlomania]

Jetzt wachen die anderen langsam auf und merken wohl das hier eine Wahnsinnsstory folgen kann.


Bid zieht an

0,28Euro

[carlomania]

In Frankfurt bekommt ihr sie vielleicht noch zu 0,28Euro

Ich würd aber besser in amerika kaufen

[carlomania]

schon 200k gehandelt

[max_m]

das wird der langersehnte Ausbruch für LAM Pharma sein!

[MCGabriel]

Hi Carlo - so schnell trifft man sich wieder.

Chart sieht genial aus - wollte eigentlich gestern schon kaufen

[carlomania]

Lest euch mal die letzten PR´S durch und macht euch euer eigenes Bild

[alexian]

dann kommt wieder die unsicherheit wegen dem vergleich...alle besinnen sich...und wieder wirds gen süden gehen

[carlomania]

Die PR müsste langsam auch kommen

Wenn der Vergleich raus ist, dann gnade uns Gott

[carlomania]

Ask bei 0,30$

[Hyper03]

Für Hammernew´s ist +/- 0 aber ein seltsamer Kurs.

[max_m]

das denke ich nicht, denn mit Patenten wird die Kohle gemacht.

Es wäre auch möglich für LAM die Patente zu verkaufen oder als Lizenz weiterzugeben usw.

Diese news hat es in sich und wird für den Rebound sorgen.

STRONG BUY!

[MCGabriel]

Hyper abwarten

Habe alle noch zu 0.28 bekommen

[carlomania]

Legt sie euch auf die Watchlist.

Aber wartet nicht zu lange


L.A.M. PHARMACEUTICAL CORP. Registered Shares DL -,0001




21.04.04 12:53:52

0,290 EUR

+3,57% [+0,01]
Börse: Frankfurt

[carlomania]

@ max_m

Genau so ist es

Wenigstens jemand der es begriffen hat worum es geht

[Hyper03]

MCG,

warum, kaufst du gleich 100000 ?

[max_m]

von wegen watchlist..

die Zeit des wartens ist vorüber. Der Abwärtstrend ist gebrochen und diese News ist nicht einer der 0815-News ("wir haben ein neues Office, usw) -

Das neue Patent erweitert in erheblichen Maße die Schlagkraft von LAM und wird neue innovative Produkte nach sich ziehen.

Da kann man die Watchlist getrost wieder einpacken.

LAM STRONG BUY!

[alexian]

ohne worte

[fairbewertet]

kann mir kurz jemand erklären was jetzt der "Hammer" bei der news sein soll
Den meisten firmen ist eine neue patentanmeldung nicht mal eine pr wert.

[Paepstin]

Eine wirklich günstige Gelegenheit, ja

Päps

[alexian]

die gelegenheit wird noch viiiiiiiiiiiiiel günstiger

[Diva]

Hallo fairbewertet,

pst .... hier können nicht alle Englisch ....

aber mir soll`s recht sein ....

cu

Diva

[max_m]

@fairbewertet

lies dir die PR nochmal genau durch, denn dort steht unter anderem folgendes:

...announced today that it has received notification from the United States Patent and Trademark Office that LAM has been granted a patent for Topical Drug Preparations, patent number 6,723,345.

Diese News besagt, dass LAM das Patent erhalten hat!

Das ist der Hammer und das ist daher auch ein STRONG BUY.

[fairbewertet]

es werden in den Tropen doch schon seit jahrzenten haltbare medikamente verkauft. was ist jetzt die besonderheit an dem lamp patent?
hilf mir mal einer auf die sprünge

[max_m]

ein Patent wird nicht für Dinge vergeben, die es schon gibt.

Das sollte als Antwort ausreichen.

[muycaro]

max, erklär Du uns doch mal als Experte, was genau das Patent so schützt und warum es Deiner Meinung nach so wertvoll ist.

[fairbewertet]

a patent
ein patent - nicht das patent

[max_m]

lest die PR.

[biketraum]

Auch eine Verbesserung eines bestehenden technischen Verfahrens kann ein neues Patent nach sich ziehen....

[Paepstin]

Das neue hier ist m.E. nach dieses hier "...sterile gelled composition..."
Also für den Endverbraucher direkt!

Päpstin

[biketraum]

Ähm, Patent hin oder her.
Was geht ab auf Xetra??????

[alexian]

bei aller liebe...max_m,

finde ich total schwach, dass du auf fragen von interessierten usern...nur so lakonisch antwortest...lest doch die pr...

man könnte denken man ist hier im falschen film...aber die lampies haben sich eben sowiese (negativ) verändert...

[Paepstin]

@Alexian

Max_m ist KEIN Lampie!

Päps

[carlomania]

Was soll denn auf Xetra abgehen.

Kurs 0,29euronen

[P47]

...LAM has been granted a patent for Topical Drug Preparations, patent number 6,723,345. The patent covers L.A.M. Ionic Polymer Matrix(TM) in its stable, sterile gelled composition as a transdermal delivery system designed to deliver therapeutic levels of a drug to specific sites below the dermal level of the skin

Topical ohne `r` bedeutet `an der Stelle einsetzbar`.

Dadurch können Medikamente die aufgrund ihrer Beschaffenheit normalerweise die Hautbarriere nicht durchdringen können in tiefere Schichten (z.B.: Wunde, Blutbahn, etc) eingeschleust.

Einfach gesagt(übertrieben): Hautcremes (z.B. Antifalten) können nicht wirken, da diese eben dieses nicht können, auch wenn uns die Kosmetikindustrie etwas anderes weismachen will.


Eine Möglichkeit des Wirkstofftransportes wurde jetzt patentiert.

Grüße.

[fairbewertet]

gut ein weiteres patent für lamp.
mehr kann ich im moment nicht daraus ersehen.
die salbe wird steril gehalten, das gibts in der medizin auch schon ein paar jährchen wenn ich mich nicht irre.
seis drum überzeugt mich nicht.

good trades

[Spekulatius_28]

RT oder Fehler?

XETRA Kurs 0,000€

ASK 0,370
Bid 0,037

[fairbewertet]

oh peinlich - Topical
danke jetzt hab ich es auch verstanden

[Paepstin]

Also das hier hatten wir schon im Jahr 2002!

LAM Pharmaceutical, Corp. ist ein in der Biomedizin tätiges Unternehmen mit Labors in Lewiston, New York, und Geschäftsräumen in Toronto, Ontario. Das Unternehmen befasst sich primär mit der Entwicklung und dem Vertrieb von neuartigen Methoden für die Wundheilung und Systemen für die subkutane Arzneimittelversorgung, durch die die Patienten u. a. von einer sichereren und wirkungsvolleren Behandlung von schlimmen Krankheiten profitieren. Die Technologie beruht auf einer Original-Ionic Polymer Matrix ("IPM"), einer patentrechtlich geschützten und patentierten Kombination aus elektrisch geladenen und nicht geladenen Molekülen, deren Eigenschaften Wunden gut und schnell heilen lassen. Die IPM-Technologie lässt sich gut mit bewährten, gut eingeführten Medikamenten kombinieren, so dass größere Mengen Medikamente auf nachhaltige Weise am Ziel ankommen, als dies sonst möglich wäre, und so eine längere therapeutische Wirkung entfalten.

Der Hauptbestandteil der Ionic Polymer Matrix ist ein Derivat der Hyaluronsäure, ein Molekül, das in der Regel in der Haut und in den Knochengelenken vorkommt. Die Hyaluronsäure ist nicht immunogen, d. h. sie löst keine Körperreaktion aus. Sie ist maßgeblich an so wichtigen biologischen Funktionen beteiligt wie der Gewebehydration und der Proteoglykanbildung (Protein- und Zuckerbildung), die wiederum die Gewebsheilung beschleunigt und einer Gewebealterung vorbeugt. Die Hyaluronsäure ist auch in hoher Konzentration in der Haut von Föten vorhanden, bei denen Wunden rasch mit nur geringer Narbenbildung heilen.

Päps

[carlomania]

Wir sollten mal warten wie die Amis starten

Charttechnisch müsste es hochgehen

[willinvest]

lasst euch von max_m nicht ärgern... ich glaube, er hat gar keine ahnung und will nur den kurs pushen!!!

willinvest

[carlomania]

Einfach mal genau lesen.


„Dies ist das fünfzehnte Patent welches LAM in den USA erteilt wurde und unterstreicht somit das Bekenntnis der Firma zu seinem geistigen Eigentum,“ sagte Joseph Slechta, President und CEO von LAM. „Diese robuste Ansammlung von geistigem Eigentum wird es LAM ermöglichen, mit der Entwicklung von weiteren Produkten zum Ausweitung des Produktangebotes der Firma fortzufahren.“



Mr Slechta schloss, „Das LAM IPM Wundgel hat bewiesen über einen hohen Grad an Wirksamkeit in der Behandlung von einer Vielzahl von schwer heilbaren Wunden , inklusive diabetischen Geschwüren und Hautrissen, zu verfügen. Wir machen einen stetigen Fortschritt im der Aufstellung von Partnern zum Vertrieb der Produkte von LAM und wir sind sehr optimistisch hinsichtlich unserer Zukunftsaussichten. “

[P47]

@ fairbewertet:
Das mit den `Tropen` war etwas sehr schwach .

Leider kenne ich den patentierten Transportmechanismus nicht, daher kann auch ich nur spekulieren.

Das Prinzip Substanzen über die Haut einzubringen ist aber genial und wird überall erforscht (z.B. Insulin, Viagra, Wundheilung, Kosmetik und und und...)

Bisher ist man jedoch immer den teuren Weg gegangen. Man versuchte bisher das Medikament so zu verändern, dass die Wirkung möglichst gleich beibt, aber die Haut passieren kann. Das ist aufwendig, da praktisch ein neues Medikament entwickelt werden muß.

Sollte ein Transportmechanismus funktionieren, kann man fast jedes schon bestehende Medikament über die Haut geben.

Vorteile:
Keine Nebenwirkungen im Magen-Darm Trakt (z.B Magenbluten bei ASS).
Geringere Dosierungen, da ein großer Teil der Medikamente vor dem Erreichen des Wirkungsortes durch die Leber eliminiert werden.
Keine Spritzen (z.B. 2-5 mal Insulinspritzen).
Bessere und kontinuierliche Abgabe des Wirkstoffes (z.B. mit einen Depotpflaster)


Das Prinzip ist genial!

Grüße.

[misterpillow]

Egal wie hier noch spekuliert wird, ich für meinen Teil habe ein paar Stücke gekauft. Wenn man den Kursverfall der letzten Tgae betrachtet, sollte diese Nachricht eigentlich einen Rebound in den USA einläuten.

[alexian]

und der kurs explodiert ins negative

[alexian]

und der kurs explodiert

[suncomesout]

@misterpillow
Den Rebound gibts erst, wenn die Einigung über die Klage publiziert wurde. Andere News sind nett, werden aber kaum etwas bewirken. Ganz im Gegenteil: Selbst wenn der Kurs dadurch kurzfristig anziehen sollte, wird dieser Anstieg von anderen genutzt um auszusteigen.

SCO

[tony_west]

so siehts aus.

[alexian]

ja, dramatisch traurig, keine news bringt was wirkliches, wenn nix mit dem vergleich bekannt wird...es wird wieder tiefer im kurs gehen

[carlomania]

Die ganzen News von China Partner usw. sind noch gar nicht im kurs enthalten.

wenn die einigung positiv für lamp ist, dann wird es eine gewaltige explosion geben.

da lege ich meine hand ins feuer

[alexian]

das glaube ich nicht mehr...warum ist heute nix passiert ? es kann doch nicht "nur" am vergleich liegen....hier stimmt was nicht...- auch sind die umsätze sehr mickrig...

[MCGabriel]

Der Zug fährt ab, wenn FRA zu hat, da verwette ich meinen Hintern.

Deckt Euch ein in FRA gibts sogar noch welche zu 0.27

Pari-Kurs ist 0.28

[carlomania]

@MC

man kann keinem zu seinem Glück zwingen.

Vielleicht kommt heute noch die PR vom Vergleich

Dann müssen die Anleger morgen zu höheren Kursen kaufen

[Paepstin]

Habt ihr schon gelesen? Im Kölner Express?
Ein unbekannter Luxemburger Lampenfinger hat einen Würstchenverkäufer überfallen und sitzt nun im Klingelpütz!


Päps

[carlomania]

@päps

Das wird doch wohl nicht JS gewesen sein

[Paepstin]

Bestimmt nicht Carlo, Jottessilein ist doch nicht so verfressen, oder?

Päps

[Paepstin]

Autsch! Da kann man ja gar nicht hingucken! Ein dickes HMMMMMMMMMMMM bildet sich wie MMMMMMMist MMMMMMüll oder MMMMMMamamia!



Päps

[Paepstin]

Hoffentlich kommt nicht der kleine Stubs, der die großen Veränderungen bringt! Und wenn, dann der Richtung Norden!



Komm Mr. Slechta, erzähle die große Einigungsstory!
Päps

[carlomania]

Kommen heute die nächsten Hammernews

[carlomania]

der abverkauf geht weiter.

es wird nur noch ins bid geschmissen.

das vertrauen ist komplett weg

[suncomesout]

Nein Carlo,
heute kommt mit Sicherheit keine News mehr von LAMP. Damit kommt wenigstens auch keine schlechte News.

SCO

[tschoki]

Tja, Mc Gabriel, dein Hintern iss also nix mehr wert, und das was du gestern noch fuer 27 als Schnaeppchen angepriesen hast ist heute nur noch 25 wert......und morgen..........reden wir nicht weiter.

In dieser Woche wird nix mehr gehen, die Kurse werden weiter broeckeln und ich gehe fest davon aus, dass bald wieder die 1 hinter dem Komma steht. Dann kommt vielleicht die News und alle freuen sich wieder um ein paar beschissene Prozente. Das Spiel geht nu wirklich schon ewig so. Ich Riesenar.......habe nur wieder mal den Ausstieg verpasst und eine Grundregel der Boerse missachtet. Gier macht blind.

T.

[tony_west]

welches VERTRAUEN?

0,3 USD.

[carlomania]

@sunco

Damit kommt wenigstens auch keine schlechte News

danke für deine Hoffnung

Muss nun weg.

Vorbereitung für meinen 30. Geburtstag am samstag erledigen

[alexian]

rette sich wer kann... - ist ja echt der hammer... fall ins bodenlose ist vorprogrammiert

[carlomania]

Die nächsten news werden kommen und dann gibt es kein halten mehr

[carlomania]

LAM Pharmaceutical CEO Interviewed by Wall Street Reporter

26.04.2004
12:17





< zurück <


Archiv


Aktuelle
Nachrichten






Druckversion

LEWISTON, N.Y., April 26 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Buletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that Joseph Slechta, President and Chief Executive Officer, was recently interviewed by Wall Street Reporter, a web-based financial news site.

Mr. Slechta provided an update on recent growth initiatives and described the Company``s product diversification strategy. The interview features a discussion of the competitive advantages of L.A.M. Ionic Polymer Matrix(TM) technology including its ability to deliver large drug molecules transdermally and to serve a wound healing gel. The expanding product distribution relationships in China, Central America and North America were highlighted and emphasis was placed emphasis on the large market opportunity in China.

The interview is accessible through the Company``s website, http://www.lampharm.com/, or by visiting Wall Street Reporter at http://www.wallstreetreporter.com/.

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., http://www.lampharm.com/, is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 14 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company``s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

Stephanie Carrington (Investors/Media) 646-536-7017 The Ruth Group

LAM Pharmaceutical, Corp.

© PR Newswire


Klicken Sie hier, um weitere aktuelle Nachrichten zum Unternehmen zu finden:

[max_m]

die NEWS hat wohl heute EINGESCHLAGEN!

[carlomania]

som, hier ist die nächste hammernews.

jetzt kann Lamp durchstarten

Lets Go lamp

LAM Pharmaceutical Announces Additional Financing and Settlement of Legal Claim

Tuesday , April 27, 2004 06:15 ET

LEWISTON, N.Y., Apr 27, 2004 /PRNewswire-FirstCall via COMTEX/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it has secured in excess of $1.2 million in additional equity financing and settled a $2.8 million legal claim against the Company for non-cash consideration.

The additional financing, obtained through a series of private placements included a further $100,000 investment by a Company Director. This equity infusion, together with strict expense management, has enabled LAM to achieve a working capital surplus. Warrants issued by the Company in relation to the private placements, with exercise prices ranging from $0.35 to $1.00, could generate an additional $2.3 million in equity funding. A $2.8 million claim relating to consulting services alleged to have been rendered in 2000 and 2001 was filed in March 2004 against LAM in the district court in Montreal, Canada. LAM has subsequently agreed to issue two million shares in full settlement of the claim.

" During the past year, we have made great strides in strengthening LAM`s balance sheet while also resolving uncertainties relating to claims made against the Company arising from certain alleged activities in 2001 and earlier. Although we felt we had an excellent case regarding this matter and that the cost to settle was high in terms of shares, we were able to conserve cash and avoid what we believed would be a lengthy, distracting and expensive legal battle," stated Joseph Slechta, President and Chief Executive Officer of LAM. " LAM is entering a new stage in its development and as such has acted to quickly resolve what we believe would be a distraction to growth. We have been able to make significant progress in developing LAM`s business prospects through achievements such as the recently announced distribution agreement with the largest pharmaceutical company in China, introduction of our veterinary product and extension of our product shelf life."

Mr. Slechta concluded, " LAM IPM Wound Gel is continuing to receive excellent feedback from the medical community and is being used by an increasing number of hospitals and wound care professionals. As LAM continues its marketing efforts, we have every confidence that sales will increase rapidly as the product continues to gain acceptance. This confidence has been underscored by the additional investment made by one of our Directors. "

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 14 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

Statements in this press release regarding our business which are not historical facts are " forward-looking statements" that involve risks and uncertainties which could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp. L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.


CONTACT: Stephanie Carrington (Investors/Media)
646-536-7017
The Ruth Group


SOURCE LAM Pharmaceutical, Corp.


CONTACT: Investors-Media, Stephanie Carrington of The Ruth Group,
[phone], for LAM Pharmaceutical, Corp.

URL: http://www.lampharm.com
http://www.prnewswire.com



Copyright (C) 2004 PR Newswire. All rights reserved.


-0-


KEYWORD: New York
INDUSTRY KEYWORD: HEA
MTC
OTC
SUBJECT CODE: FNC
LAW


STOCK SYMBOLS: [(lamp)]

[carlomania]

ask bei 0,30

[carlomania]

ask 0,33

[carlomania]

Schaut euch mal den chart an

Hier zeichnet sioch ein sher schönes W ab

[carlomania]

Haltet eure lampen gut fest

[alexian]

[carlomania]

Medizinisches Team von LAM Pharmaceutical unterstützt Produkttraining des ...
04.05.2004 (12:26)

Medizinisches Team von LAM Pharmaceutical unterstützt Produkttraining des chinesischen medizinischen Fachpersonals

LEWISTON, N.Y., Dienstag, 04. Mai 2004 -- LAM Pharmaceutical, Corp. (WKN 631629) ein in der Biomedizin tätiges Unternehmen mit der Konzentration auf die Entwicklung und Kommerzialisierung eines neuen Wundheilung- und transdermalen Verabreichungssystems, gibt heute bekannt, dass das gleiche medizinische Team, das in den USA die Studie an Menschen über das LAM IPM Wundgel geleitet hat, sich verpflichtet hat den Markteintritt der Firma in China zu unterstützen. Begrüsst und befürwortet von LAM’s Vertriebspartner in China wird das Team mit Sinopharm zusammenarbeiten, um sicherzustellen, dass das chinesische medizinische Fachpersonal, angefangen mit grossen Krankenhäusern in Peking, Shanghai und Guangzhou, die geeignete Ausbildung für das IPM Wundgel erhält.

Joseph SLechta, President und CEO von LAM Pharmaceutical Corp. kommentierte, „Wir sind sehr erfreut über die Verpflichtung von dem US Medical Team unsere chinesischen Initiativen zu unterstützen. Diese Anleitung des chinesischen Wundheilungs-Fachpersonals wie das Gel anzuwenden ist, wie zu verbinden und wie Wunden, die mit dem Gel behandelt wurden, zu betreuen sind, ist ein wichtiger Schritt hin zu der Erreichung maximaler Ergebnisse. Der Teamwork-Ansatz wird die positive Einführung in den sehr grossen chinesischen Marktplatz erleichtern und letztlich zur Beschleunigung auf dem Pfad zu umfassenden Verkäufen beitragen.“

Für die Richtigkeit der Übersetzung wird keine Haftung übernommen! Beachten Sie die Orginalmitteilung im Anhang

[carlomania]

ask bei 0,32$

kommt nun die Invasion der Lampen

[carlomania]

LAM Pharmaceutical`s Licensee IXORA Bio Medical Commences Commercial Sales of Female Sexual Enhancement Product

Wednesday, May 12, 2004 06:15 ET

LEWISTON, N.Y., May 12, 2004 /PRNewswire-FirstCall via COMTEX/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that Ixora Bio Medical Company Inc., a licensee of LAM, has commenced commercial sales of its first product, " Ixora(TM) for Women" , a non-prescription female sexual enhancement product Ixora has licensed from LAM.

John Easton, Chief Executive Officer of Ixora Bio Medical, stated, " The commercial release of " Ixora(TM) for Women" in the United States and Canada comes at a time when the medical community, media and public are recognizing that sexual health and optimal sexual function are an essential component of one`s overall well being. Mr. Easton continued, " Having completed four years of extensive development, " Ixora(TM) for Women" is ready to answer the rapidly increasing demand for an upscale product that addresses the issue of women`s sexual function."

Mr. Easton concluded, " With `Ixora(TM) for Women` available through doctors` offices, women`s health clinics, direct sales and on the Ixora`s web site (www.Ixoraforwomen.com), Ixora expects that the market size and strong demand backed by the upcoming media launch will all contribute to strong sales ramp up throughout 2004."

Dr. Jack Barkin, Urologist-in-chief and chief of surgery at the Humber River Regional Hospital in Toronto, Canada stated, " Women, especially as they reach menopause, have a loss of hormonal support that contributes to decreased sexual desire. The introduction of `Ixora(TM) for Women` provides women and their partners a natural solution to sexual enhancement."

Joseph Slechta, President and Chief Executive Officer of LAM, remarked, " We are pleased that Ixora has commenced commercial sales, marking the third product introduction based on LAM`s proprietary IPM technology. As LAM`s IPM Wound Gel, our veterinary product, and `Ixora(TM) for Women` all gain acceptance in their markets, we look forward to developing more products based on our remarkable technology."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company with laboratories in Lewiston, New York, and business offices in Toronto, Canada and Beijing, China. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 15 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

About Ixora Bio Medical Company Inc.

Ixora Bio Medical Company is a biomedical company with headquarters in New York City. Ixora holds a world wide exclusive license from LAM for sexual dysfunction products based on LAM`s patented proprietary IPM Ionic Polymer Matrix transdermal delivery platform. The Company`s current focus is to develop and commercialize sexual enhancement products. More information about Ixora can be obtained by visiting www.Ixoraforwomen.com.

Statements in this press release regarding our business which are not historical facts are " forward-looking statements" that involve risks and uncertainties which could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.


Stephanie Carrington
(Investors/Media)
646-536-7017
The Ruth Group


SOURCE LAM Pharmaceutical, Corp.


CONTACT: Stephanie Carrington of The Ruth Group, [phone], for
LAM Pharmaceutical, Corp.

URL: http://www.Ixoraforwomen.com
http://www.prnewswire.com

[tdwzb]

commercial sales!!

das ist das entscheidende
könnt ne party in USA geben
OTCBB ist ja unberechenbar

[tony_west]

heute wird die 0,3 Euro übersprungen!

[carlomania]

aber locker

[carlomania]

Form 10QSB for LAM PHARMACEUTICAL CORP


--------------------------------------------------------------------------------

14-May-2004

Quarterly Report


Item 2 Management`s Discussion and Analysis of Financial Condition and Resultsof Operation
The following sets forth certain financial data with respect to us and isqualified in its entirety by reference to the more detailed financial statementsand notes included elsewhere in this quarterly report on form 10-QSB. Thefollowing contains statements that constitute "forward looking statements"within the meaning of Section 21E of the Securities Exchange Act of 1934. Insome cases, you can also identify forward-looking statements by terminology suchas "may," "should," "could," "would," "predicts," "potential," "continue,""expects," "anticipates," "future," "intends," "plans," "believes," "estimates"and similar expressions. All forward-looking statements are based on assumptionsthat we have made based on our experience and perception of historical trends,current conditions, expected future developments and other factors that webelieve are appropriate. These statements are subject to numerous risks anduncertainties, many of which are beyond our control, including the statementsset forth under "Risk Factors." No forward-looking statement can be guaranteed,and actual results may differ materially from those projected. We undertake noobligation to publicly update any forward-looking statement, whether as a resultof new information, future events or otherwise.

Overview

We are the owner of a proprietary wound healing and transdermal drugdelivery technology that involves the use of an original L.A.M. Ionic PolymerMatrix™ technology for the purpose of delivering, enhancing and sustaining theaction of certain established therapeutic agents. Our corporate objective is todevelop, market and license wound healing and transdermally delivered drugs,both prescription and over-the-counter, using our patented L.A.M. Ionic PolymerMatrix™ technology. We intend to seek out corporate alliances and co-marketingpartnerships where other drugs and topical products can be enhanced by ourL.A.M. IPM™ technology.

We received clearance of our 510(k) pre-market notification from the FDA inApril 2002 and commenced limited commercial sales in August of 2002. SinceAugust 2002, we have continued efforts to develop commercial sales in the UnitedStates market. In addition, we have pursued a strategy of seeking regulatoryapproval to sell our L.A.M. IPM Wound Gel™ in additional markets outside of theUnited States. In March 2004 we learned that we received approval to import andsell our L.A.M. IPM Wound Gel™ in China.

Our revenue in the first quarter of 2004 decreased to $19,000 compared to$31,000 in the prior year and our operating expenses decreased from $398,000 in2003 to $339,000 in 2004. Net loss for the quarter increased to $977,000 in 2004compared to $918,000 in 2003.

Selected Financial Data

The summary financial data set forth below with respect to the statementsof operations for the three months ended March 31, 2004 and 2003 and withrespect to the balance sheets as at March 31, 2004 and December 31, 2003, arederived from, and should be read in conjunction with the financial statementsand the related notes.

Income Statement Data



For the Three Months Ended March 31, March 31, Percentage 2004 2003 Change ---------------- ------------ ------------- Sales $ 18,636 $ 30,844 (40 %) Operating Expenses Cost of Goods Sold 3,963 6,788 (42 %) General and Administration 175,152 159,997 9.5 % Marketing and Business Development 128,194 152,105 (16 %) Research and Development 31,239 79,323 (61 %) ---------- --------
Total Operating Expenses 338,548 398,213 (15 %) Financial Accounting Expenses 96,668 (49,662 ) Provision for Lawsuit Settlement 560,000 — Provision for Arbitration Settlement — 600,000 ---------- --------
Net Loss $ (976,580 ) $ (917,707 )

Table of Contents

Balance Sheet Data:



As at --------------------------------------- March 31, 2004 December 31, 2003 ----------------- ------------------- Current Assets $ 1,338,920 $ 590,295 Total Assets 2,048,201 1,281,858 Current Liabilities 817,417 1,027,561 Total Liabilities 1,174,322 1,384,466 Working Capital (Deficiency) 521,503 (437,266 ) Stockholders` Equity (Deficit) 873,879 (102,608 )
Results of Operations

Three months Ended March 31, 2004 compared with Three Months Ended March 31,

Sales

Sales during the three months ended March 31, 2004, amounted to $19,000, adecrease of 40% over sales in the first quarter of 2003 of $31,000, howeversales rose by 7% over sales in three months ended December 31, 2003. In January2004, we signed a distribution agreement with China National PharmaceuticalTrade Corporation to distribute our L.A.M. IPM Wound Gel™ in China. We believethat through the signing of this distribution agreement we will achieveincreased sales later in 2004.

Cost of Goods Sold

Cost of Goods Sold for the three months ended 2004 were $4,000,representing a decrease of $3,000, or approximately 42%, from $7,000 in 2003.The gross profit percentage of 79% remained constant for the first quarter of2004 when compared to 78% for the first quarter of 2003.

General and Administrative Expenses

General and administrative expenses for the three months ended March 31,2004 increased 9.5% to $175,000 from $160,000 for the three months ended March31, 2003. The increase included costs attributable to the special meeting ofshareholders held in March 2004 and expenses related to our private placement.Decreases in investor relations, salaries and benefits and insurance reflectedour continued efforts to reduce operating expenses.

The primary components of general and administrative expenses for the threemonths ended March 31, 2004 and 2003 were as follows:



Three months ended March 31, ------------------------- 2004 2003 ----------- ----------- Officers` salaries $ 12,750 $ 9,375 Employee salaries and benefits 25,671 28,332 Investor relations 7,855 16,578 Financial consulting 13,011 — Legal and auditing (including SEC filings) 50,380 46,008 Insurance 3,231 15,479 Shareholder special meeting expenses 7,496 — Other expenses 54,758 44,225 ----------- ----------- Total 175,152 159,997

Table of Contents

Marketing and Business Development Expense

Marketing and business development expense for the three months endedMarch 31, 2004 decreased 16% to $128,000 from $152,000 for the three monthsended March 31, 2003. The decrease reflects the reduction in personnel whichoccurred in the second quarter of 2003.

Research and Development Expense

Research and development expenses for the three months ended March 31, 2004decreased 61% to $31,000 from $79,000 for the three months ended March 31, 2003.We have chosen to reduce our research and development expenditures in order tofocus on establishing our existing products in the market place. As our productsobtain acceptance we will increase our research and development expenditures andaccelerate the development of additional products.

Share and Option Grants

We are required to recognize non-cash expenses which represent the deemedfair value of grants of stock options and of stock for services, calculated inaccordance with United States generally accepted accounting principles. Thesedeemed non-cash costs, which are accounted for by correspondingly increasing ourpaid in capital, increased to $52,000 for the three months ended March 31, 2004from $(69,000) for the three months ended March 31, 2003. The non-cash expensesin 2004 included costs attributed to options and shares granted to consultantsand directors for services performed. The negative expense in 2003 resulted fromour ability to renegotiate a contract with a third party in which the number ofshares to be issued to the third party was reduced.

Warrant Premium

The expense of $25,000 for the three months ended March 31, 2004 representsthe fair value of the warrants issued to shareholders in connection with ourprivate placement.

Provision for Legal Settlement

In March 2004, a consultant filed a lawsuit against us and one of ourdirectors with the District Court of Montreal in Quebec, Canada in the amount of$2.8 million alleging that we failed to issue shares of our common stock to theindividual for services rendered during the periods of 2001 and 2002. OnApril 26, 2004 we reached an out of court settlement of the lawsuit with theconsultant which resulted in the issuance of two million shares of our commonstock. We have recorded $560,000, the effect of the settlement, in the financialstatements for the period ended March 31, 2004.

Liquidity and Sources of Capital

Three Months ended March 31, 2004

Our cash and cash equivalents as of March 31, 2004 was $783,000. Theworking capital increased from a deficiency of approximately $(437,000) as ofDecember 31, 2003 to a working capital surplus of approximately $522,000 as ofMarch 31, 2004.

Our operations used approximately $458,000 in cash during the three monthsended March 31, 2004 compared to $219,000 used in the same period in the prioryear. This was primarily due to a reduction of accounts payable in the currentperiod of $147,000 compared to an increase in accounts payable of $131,000 inthe same period in the prior year.

During this period we also invested $35,000 in patents and trademarks.

During the three months ended March 31, 2004, funds were raised principallyfrom the exercise of warrants in the amount of $259,000 and from subscriptionagreements for the issuance of our common stock in the amount of $991,000 asfollows:


Table of Contents

During the three months ended March 31, 2004 we sold units of our commonstock in which each unit consists of 1,000 shares of our common stock plus 750warrants. Each warrant will entitle the holder to purchase one share of commonstock as follows:

• One third of warrants may be exercised at any time prior to June 30,

2005 at prices ranging from $0.35 to $0.60 per share;
• One third of warrants may be exercised at any time prior to December 31, 2005 at prices ranging from $0.35 to $0.75 per share;
and
• One third of warrants may be exercised at any time prior to June 30,
2006 at prices ranging from $0.55 to $1.00 per share
Through this private placement we sold 5,512,000 shares of our commonstock, plus warrants for the purchase of an additional 4,134,000 shares forproceeds amounting to $1,230,000 to 33 investors of which $991,000 was receivedprior to March 31, 2004. As of March 31, 2004 we have not issued the commonstock in relation to the private placement.

Application of Critical Accounting Policies

Our financial statements and accompanying notes are prepared in accordancewith generally accepted accounting principles in the United States. Preparingfinancial statements requires management to make estimates and assumptions thataffect the reported amounts of assets, liabilities, revenue, and expenses. Theseestimates and assumptions are affected by management`s application of accountingpolicies. Critical accounting policies include revenue recognition, inventoryvaluation and accounting for income taxes.

We recognize revenue in accordance with Staff Accounting Bulletin No. 101,"Revenue Recognition in Financial Statements". We recognize revenue when it isrealized or realizable and earned. We consider revenue realized or realizablewhen the product has been shipped to the customer, the sales price is fixed ordeterminable and collectibility is reasonably assured. We reduce our revenue forestimated customer returns.

Inventory is comprised of finished goods and raw materials and is stated atthe lower of cost or market. Cost is determined by the first-in, first-outmethod and market is based on the lower of replacement cost or net realizablevalue.

Statement of Financial Accounting Standards No. 109, "Accounting for IncomeTaxes," establishes financial accounting and reporting standards for the effectof income taxes. The objectives of accounting for income taxes are to recognizethe amount of taxes payable or refundable for the current year and deferred taxliabilities and assets for the future tax consequences of events that have beenrecognized in an entity`s financial statements or tax returns. All deferred taxassets have been fully reserved against due to the uncertainty as to when orwhether the tax benefit will be realized.

[carlomania]

es läuft alles nach Plan.

LAMP ist auf einem Guten Weg
die nächsten Quartalszahlen werden es zeigen.

[carlomania]

http://www.bbbiotech.ch/index.cfm?action=industrienews.detai…

[carlomania]

0,27

[carlomania]

LAMP TIP Freitag den 18. Juni OTCBB

Ich bitte um rege Beteiligung.

Denn das wird die woche der Woche.

Alf 0,35 Dollar
Carlo 0,46 Dollar
somart 0,48 Dollar
JohannesBoos 0,31 Dollar
Jamag 0,365
Bombenleger 0,45 Dollar
Ichotolot 0,34 Dollar
Ralph 0,38 Dollar
Oski 0,36 Dollar
JRM 0,47 Dollar
Emsi 0,50 Dollar
Gitarre 0,44 Dollar
JS 200 0,35 - 0,36 Dollar

So leute , was ist das für eine MUDE Laden.

Her mit euren Tipps

[Immobilienhai2000]

up